Autoantibodies against type I IFNs in patients with critical influenza pneumonia

Simple item page
dc.contributor.authorZhang, Qian
dc.contributor.authorPizzorno, Andres
dc.contributor.authorMiorin, Lisa
dc.contributor.authorBastard, Paul
dc.contributor.authorGervais, Adrian
dc.contributor.authorLe Voyer, Tom
dc.contributor.authorBizien, Lucy
dc.contributor.authorManry, Jeremy
dc.contributor.authorRosain, Jeremie
dc.contributor.authorPhilippot, Quentin
dc.contributor.authorGoavec, Kelian
dc.contributor.authorPadey, Blandine
dc.contributor.authorCupic, Anastasija
dc.contributor.authorLaurent, Emilie
dc.contributor.authorSaker, Kahina
dc.contributor.authorVanker, Martti
dc.contributor.authorSaerekannu, Karita
dc.contributor.authorGarcia-Salum, Tamara
dc.contributor.authorFerres, Marcela
dc.contributor.authorLe Corre, Nicole
dc.contributor.authorSanchez-Cespedes, Javier
dc.contributor.authorBalsera-Manzanero, Maria
dc.contributor.authorCarratala, Jordi
dc.contributor.authorRetamar-Gentil, Pilar
dc.contributor.authorAbelenda-Alonso, Gabriela
dc.contributor.authorValiente, Adoracion
dc.contributor.authorTiberghien, Pierre
dc.contributor.authorZins, Marie
dc.contributor.authorDebette, Stephanie
dc.contributor.authorMeyts, Isabelle
dc.contributor.authorHaerynck, Filomeen
dc.contributor.authorCastagnoli, Riccardo
dc.contributor.authorNotarangelo, Luigi D.
dc.contributor.authorGonzalez-Granado, Luis I.
dc.contributor.authorDominguez-Pinilla, Nerea
dc.contributor.authorAndreakos, Evangelos
dc.contributor.authorTriantafyllia, Vasiliki
dc.contributor.authorRodriguez-Gallego, Carlos
dc.contributor.authorSole-Violan, Jordi
dc.contributor.authorRuiz-Hernandez, Jose Juan
dc.contributor.authorRodriguez de Castro, Felipe
dc.contributor.authorFerreres, Jose
dc.contributor.authorBriones, Marisa
dc.contributor.authorWauters, Joost
dc.contributor.authorVanderbeke, Lore
dc.contributor.authorFeys, Simon
dc.contributor.authorKuo, Chen-Yen
dc.contributor.authorLei, Wei-Te
dc.contributor.authorKu, Cheng-Lung
dc.contributor.authorTal, Galit
dc.contributor.authorEtzioni, Amos
dc.contributor.authorHanna, Suhair
dc.contributor.authorFournet, Thomas
dc.contributor.authorCasalegno, Jean-Sebastien
dc.contributor.authorQueromes, Gregory
dc.contributor.authorArgaud, Laurent
dc.contributor.authorJavouhey, Etienne
dc.contributor.authorRosa-Calatrava, Manuel
dc.contributor.authorCordero, Elisa
dc.contributor.authorAydillo, Teresa
dc.contributor.authorMedina, Rafael A.
dc.contributor.authorKisand, Kai
dc.contributor.authorPuel, Anne
dc.contributor.authorJouanguy, Emmanuelle
dc.contributor.authorAbel, Laurent
dc.contributor.authorCobat, Aurelie
dc.contributor.authorTrouillet-Assant, Sophie
dc.contributor.authorGarcia-Sastre, Adolfo
dc.contributor.authorCasanova, Jean-Laurent
dc.date.accessioned2025-01-20T21:01:21Z
dc.date.available2025-01-20T21:01:21Z
dc.date.issued2022
dc.description.abstractIn an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine.
dc.description.abstractAutoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 x 10(-5)), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old.
dc.fuente.origenWOS
dc.identifier.doi10.1084/jem.20220514
dc.identifier.eissn1540-9538
dc.identifier.issn0022-1007
dc.identifier.urihttps://doi.org/10.1084/jem.20220514
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/92864
dc.identifier.wosidWOS:000890308700001
dc.issue.numero11
dc.language.isoen
dc.revistaJournal of experimental medicine
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAutoantibodies against type I IFNs in patients with critical influenza pneumonia
dc.typeartículo
dc.volumen219
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas